1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 33; p. S1188
Main Authors Lang, J., Tagawa, S.T., Slovin, S., Emamekhoo, H., Rathkopf, D., Abida, W., Autio, K., Xiao, H., Molina, A.M., Eickhoff, J., Sperger, J.M., Dehm, S., Nanus, D.M., Kyriakopoulos, C.E.
Format Journal Article
LanguageEnglish
Published 01.09.2022
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.1892